Kineta's Top Scientist Makes Major Stock Move Following Merger Approval

Rhea-AI Filing Summary

Thierry Guillaudeux, Chief Scientific Officer of Kineta, reported multiple securities transactions on June 23-25, 2025:

• Exercised 225,000 stock options at $0.36 per share on June 23
• Disposed of 47,647 shares at $0.26 per share through tax withholding (Form F)
• Received 23,100 new shares on June 25 at $0 cost

These transactions occurred in connection with the merger agreement between Kineta and TuHURA Biosciences. Per the Optionholder Treatment Agreement dated June 16, 2025, and the merger agreement dated December 11, 2024 (amended May 5, 2025), Guillaudeux's options under the 2022 Equity Incentive Plan became fully vested on June 23, 2025. Following all transactions, Guillaudeux directly owns 217,333 shares of common stock.

Insider Trade Summary

225,000 shares exercised/converted

Mixed 4 txns

Insider Guillaudeux Thierry

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	23,100	$0.00	--
Exercise	Stock Option (Right to Buy)	225,000	$0.00	--
Exercise	Common Stock	225,000	$0.36	$81K
Tax Withholding	Common Stock	47,647	$0.26	$12K

Holdings After Transaction: Common Stock — 217,333 shares (Direct); Stock Option (Right to Buy) — 0 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guillaudeux Thierry

(Last) (First) (Middle)

C/O KINETA, INC.

7683 SE 27TH STREET, SUITE 481

(Street)

MERCER ISLAND WA 98040

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KINETA, INC./DE [ KANT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/23/2025		M		225,000	A	$0.36	246,696	D
Common Stock	06/23/2025		F		47,647	D	$0.26	194,233	D
Common Stock	06/25/2025		A		23,100	A	$0	217,333	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.36	06/23/2025		M			225,000	(1)	04/13/2024	Common Stock	225,000	$0	0	D

Explanation of Responses:

1. Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025.

	/s/ Nanette Agustines, as Attorney-in-Fact	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Kineta's (KA) Chief Scientific Officer make on June 23, 2025?

On June 23, 2025, Thierry Guillaudeux, Kineta's Chief Scientific Officer, exercised 225,000 stock options at $0.36 per share and subsequently disposed of 47,647 shares at $0.26 per share. Following these transactions, he held 194,233 shares directly.

How many stock options did Kineta's (KA) CSO exercise in June 2025?

Kineta's CSO exercised 225,000 stock options with an exercise price of $0.36 per share on June 23, 2025. After this exercise, he no longer held any remaining stock options from this grant, which had an original expiration date of April 13, 2024.

Why did Kineta (KA) insider stock options vest early in June 2025?

The stock options vested fully on June 23, 2025, due to the Optionholder Treatment Agreement dated June 16, 2025, and the Agreement and Plan of Merger with TuHURA Biosciences, Inc. This accelerated vesting was approved by stockholders at the Special Meeting held on June 23, 2025.

How many shares did Kineta's (KA) CSO Thierry Guillaudeux receive on June 25, 2025?

Thierry Guillaudeux received 23,100 shares of Kineta common stock on June 25, 2025, as an acquisition (A) at $0 cost, bringing his total direct ownership to 217,333 shares.